OWKIN CEO Outlines AI's 'Transfer Learning' Promise In Drug Discovery

Privately owned startup OWKIN will use $11m raised in a Series A funding for new hires and building its predictive artificial intelligence platform which it will launch in early 2019 to speed drug discovery.

Big data
OWKIN Aims To Use Its Predictive AI Platform in healthcare discovery • Source: Shutterstock

Nascent artificial intelligence (AI) group OWKIN is $11m in newly raised funds to hire medical specialists and prepare its proprietary Socrates technology platform for launch next year aimed at helping pharma R&D teams and hospital researchers discover and develop new targets, biomarkers and drugs faster.

The privately owned startup is building a privacy-preserving platform that uses machine-learning based modeling to analyze molecular and imaging libraries as well as patient datasets to uncover complex biomarker patterns that cause disease

More from Strategy

More from Business